Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engage with the FDA on the data needed to prove the drug's safety and effectiveness, potentially speeding up approval. Orvida is currently conducting a Phase 1b trial with topline results expected by the end of 2026. This milestone is significant as there are currently no approved treatments for Olmsted syndrome, which severely impacts patients' quality of life.
Orvida Pharma's FDA acceptance of KM-023 into the Rare Disease Evidence Principles process provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 14, 2026 18:11 WIB: out of 150 priced US health-sector stocks, 103 rose and 40 fell. Notable movers include AZN at USD 158.62 with a 1-day change of +1.80% and typical hold time of 127 days, NVS at USD 144.94 with a 1-day change of +1.78% and typical hold time of 82 days, and DGX at USD 227.06 with a 1-day change of -1.52% and typical hold time of 56 days.
DMC Global Inc. will announce its financial results for the third quarter ending September 30, 2026, on October 27 after the stock market closes. The company will hold a conference call and webcast to discuss the results, providing investors with ins...
Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...
Radware introduced its Model Context Protocol (MCP) Server Protection solution to help organizations secure the integration layer where AI agents connect to enterprise applications and workflows. This new security tool provides visibility into MCP in...
The global anthracite market, valued at $11.9 billion in 2025, is projected to grow to $16.8 billion by 2035 with a 3.5% CAGR. Growth is fueled by rising demand in steel production, water filtration, and advanced industrial uses due to anthracite's h...
Intel's stock price has surged nearly threefold in 2026, reflecting strong market performance this year. However, an investment of $10,000 made in Intel shares back in 2016 would still have underperformed compared to simply investing in the S&P 500 i...
